You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.
Cancel Ok
Arena Pharma THIS COFFEE RUN SPARKED AN IDEA TO DESIGN TRIALS WITH PATIENTS' LIVES IN MIND. RELENTLESS THINKING DOESN'T JUST DRIVE US. IT DEFINES US.
Arena Pharma

OUR PIPELINE

We're pursuing every opportunity to develop and bring our investigational medicines* to patients.
Gastroenterology >
ULCERATIVE COLITIS
 UC 52 UC 52
Phase 3
UC 12 UC 12
Phase 3
Phase 2
CROHN'S DISEASE
Phase 2/3
EOSINOPHILIC ESOPHAGITIS
Phase 2
INFLAMMATORY BOWEL DISEASE
Exploratory
IRRITABLE BOWEL SYNDROME PAIN
Phase 2
Dermatology >
ATOPIC DERMATITIS
Phase 3 Planning
ALOPECIA AREATA
Phase 2
PALMOPLANTAR PUSTULOSIS
Phase 2b Planning
HIDRADENITIS SUPPURATIVA
Exploratory
Cardiovascular >
ACUTE HEART FAILURE
Phase 2
MICROVASCULAR OBSTRUCTION
Phase 2
RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
Phase 2
Research Partnerships >
BEACON DISCOVERY
MULTIPLE IMMUNE & INFLAMMATORY TARGETS
Preclinical
Licensed or Partnered >
RALINEPAG
PULMONARY ARTERIAL HYPERTENSION
Phase 3
MULTIPLE ASSETS
RARE CENTRAL NERVOUS SYSTEM TARGETS
Preclinical to Phase 1
Preclinical
*Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority.
**RIST4721 is being developed by Aristea Therapeutics, Inc. in collaboration with Arena. Arena has an exclusive option to acquire Aristea and the RIST4721 program.
If you have questions about an Expanded Access or Compassionate Use Program, please contact medinfo@arenapharm.com